ABSTRACT
formation of siderophore -antibiotic conjugates known as Sideromycins. These are the microbe selective compounds that put together two utilitarian molecules, a si derophore and an antibiotic, into one structural scaffold. The siderophore part of this conjugate is able to scavenge iron and is recognized by cellular Fe-Siderophore uptake systems, while the other part of conjugate bears an antibiotic activity that uses the siderophore as a Trojan horse and mediates iron transport mediated drug delivery.
The antibiotic molecule recruits the siderophore as a "Trojan horse" vehicle, taking advantage of the Fe-siderophore uptake system, to enter the microbial cell. The drug conjugate usually also consists of a linker for attac hing the drug to the siderophore. The linker allows controlled, chemical or enzymatic, release of drugs in the target bacterial cell. On reaching into the cell, the side rophore-drug conjugate kills the cell by releasing the drug or by acting as an intact antibacterial agent or by blocking further iron acquisition. The siderophore -antibiotic conjugates are of two types -natural and synthetic: These are siderophore transport system to gain access to the cell after gaining entry inside the cell -exert antibacterial activity by inhibiting protein synthesis.
b. Synthetic Siderophore-antibiotic conjugates-These can be prepared -using antibiotics with improved cell permeability and reduced susceptibility to resistance mechanisms. Siderophores can be bound to potent antibiotics such as beta lactam (Carbacephalosporins), erythromycin, sulphonamides, spiramycin, vancomycin, nalidixic acid, norfloxacin, etc. Antifungal agents -such as 5-flourocytosine and neoenactins can also be conjugated and used against fungi. The results indicate that these conjugates give better results and this siderophores mediated drug delivery is remarkably effective. Microbes recognize the siderophore component as an iron delivery agent and assimilate the conjugate and commit suicide as the attached drug is lethal to them. The siderophoreantibiotic conjugates can also be used against pathogenic
INTRODUCTION
The concern over increasing antibiotic resistance in pathogenic bacteria, due to their capacity to adapt by natural selection, is wobbling the medical field all over the world. It has forced the pharmaceutical industries to search for newer effective antibiotics. To overcome the drug resistance problem, the sensible use of antibio tics available with us must be respected. One newer attitude that has been explored to resolve the problem is to smuggle the antibiotic molecule into the bacterial cell by binding it to a siderophore molecule (the Trojan Horse strategy).
Most organisms require iron as an essential element in a variety of metabolic and informational cellular pathways. More than 100 enzymes acting in primary and secondary metabolism possess iron containing cofactors (1) . Although iron is abundantly present in the environment, ionic forms of iron are insoluble under physiological conditions and hence are difficult to assimilate for microorganisms (2) . Three to four gram of iron is generally present in Human body, out of which haemoglobin and myoglobin acquire the major share of 70% (3). Mammalian iron-binding proteins, such as transferrin and lactoferrin, reduce the amount of iron available to the microbes. The iron acquiring skill of pathogens is essential for their ability to cause infection in animal hosts and to establish the hostparasite relationship (4 -7). Under such iron-depriving conditions, the aerobic and facultative anaerobic bacteria and other microorganisms frequently produce organic chelates that combine with inorganic iron and greatly enhance its solubility. These microorganisms also produce the unique outer membrane proteins (OMPs) which serve to recognize process and transport the siderophore-iron complex (es) into cell. These chelates, which were designated earlier as siderochromes, sideramines, and sideromycins, are now conveniently termed as Siderophores (meaning in Greek: sideros = iron and phores = bearer). Siderophores are technically defined as the ferric iron specific, low molecular weight (<1500) compounds, which solubilize and transport iron in to the cell (8-11).
Classes of Microbial Siderophores
A large number of Siderophores produced by different microorganisms have been documented. The most common Siderophores can be classified traditionally as phenol-catecholates and hydroxamates, depending upon the chemical moieties that are involved in coordination of the ferric iron (12) , while siderophores that contain neither of these ligand systems have extended the classification to a third main class i.e. carboxylate siderophores. Particularly the first two classes exhibited a high structural diversity and were found in a vast number of microorganisms. Fungi predominantly produce hydroxamate type of Siderophores whereas bacteria and related prokaryotes produce hydroxamate as well as catecholate types (13, 14) . The siderophores of fluorescent Pseudomonas spp. and Escherichia coli are most extensively studied. The succinate medium is widely used for production of siderophores by Pseudomonas spp. by a process of fermentation. The appearance of parrot green colour in the medium is an indication of production of siderophores ( Figure 1 ). The siderophore produced can be extracted and purified for further studies by using phenol-chloroform solvent extraction method ( Figure 2 ).
Some Medically Important Bacterial Siderophores
Medically important bacterial species producing siderophores are summerized in Table 1 .
Medical Applications of Siderophores
The obligate nutritional requirement for iron by multiple drug resistant pathogens can be exploited to control its infection. The three fundamental perceptions of iron dependant pathogen control include the Trojan horse concept to facilitate the cellular uptake of antibiotics, artificial iron starvation by using siderophores or antagonists that cannot be utilized as an iron source by the pathogen and inhibition of iron metabolism pathways (23) . Siderophores and their substituted derivatives have a large number of applications in medical sciences. Siderophores have potential applications in the treatment of some human diseases and infections. These are as follows:
Selective Drug Delivery -Trojan horse strategy (Siderophore-antibiotic conjugates -Sideromycins)
Siderophores can be used for selective delivery of antibiotics in antibiotic resistant bacteria. It is a newer antimicrobial approach to defeat drug resistant bacteria. It is the potentially powerful application that uses the iron transport abilities of siderophores to carry drugs into cells by preparation of conjugates between siderophores and antimicrobial agents. It uses siderophores as mediators to facilitate the cellular uptake of antibiotics. This interaction of antibiotic with siderophores results in a 
b. Sickle cell disease
It is a lifelong genetic disorder characterized by abnormal, rigid and sickle shaped red blood cells (RBCs) that needs repeated blood transfusions. Iron overload in these cases is likely to be detected after 20 transfusions. Iron overload can be detected by monitoring serum ferritin level but study of liver biopsy is more accurate test for the diagnosis. Desferal is the treatment for sickle cell di sease.
c. Thalassemia major
It is a genetically transmitted haemoglobin abnormality that leads to anemia. It needs multiple transfusions because of which iron overload is likely to occur after the first 10-20 transfusions (near the age of three years). Iron overload is monitored by serum ferritin level (serum ferritin level > 1000 microgram/L is an indicator) but this test is not reliable, hence for confirmation liver biopsy and MRI are used. Desferal is the drug used for the treatment of thalassemia major (31 -35).
Siderophores in the Treatment of Malaria -Antimalarial Activity
Some siderophores have been found to be useful in the treatment of malaria caused by Plasmodium falciparum. Desferrioxamine B produced by Streptomyces pilosus (Now produced by chemical synthesis also) is active against P. falciparum in vitro as well as in vivo. This agent enters the parasite and causes intracellular iron depletion. This agent conjugated with methylanthranilic acid shows 10-fold higher in vitro activity against P. falciparum, which could be increased further by using nalidixic acid as a conjugate against multidrug resistant P. falciparum. The mode of action of this conjugate is metal-catalyzed oxidative DNA damage (36 -38).
Siderophres in the Removal of Transuranic Elements
The development of electricity generation by nuclear energy has led to increased human exposure to transuranic elements such as aluminium. Siderophores can be used to remove such elements from the body.
a. Removal of Aluminium
Aluminium overload occurs in dialysis encephalopathy (is a major complication of long -term dialysis, which is caused by the accumulation of aluminium in the brain) and dialysis patients with end stage renal failure (ESRF). In the treatment of chronic aluminium overload -Desferol can mobilize and chelate tissue bound aluminium forming an aluminoxamine complex, which are freely soluble in water and are readily excreted through the kidneys (urine) and may also be excreted in faeces. Desferol forms complex with aluminium ions, hence can be used in the treatment of aluminium overload. It is given as a single dose, slow intravenous infusion -50 mg/kg (15 mg/kg/h). In children with ESRF-15-20mg/kg is given. In chronic aluminium overload with ESRF -5.0 mg/kg IV infusion (15 mg/kg/h) once weekly for three months. Monitoring Criteria -Aluminum level is to be monitored properly. The aluminium level of 60 ng/ml and aluminium related bone diseases (diagnosed by bone biopsy) are the criteria for monitoring the same.
b. Removal of Vanadium
Desferal can also be used for removal of vanadium from the body. It has been found that in rats, desferal reduced the vanadium content in kidney by 20%, in lungs by 25% and in liver by 26%. It has been found that desferal increases the urinary and faecal excretion of vanadium. It is poorly absorbed through gastrointestinal tract (GIT). Inhalation causes adverse effects on the respiratory tract. Oral / inhalation exposures -affect blood parameters and create liver problems, neurological problems and problems in other organs. These effects have been studied in rats (39 -42).
Other Uses of Siderophores
a. Deoderant -Siderophore from Klebsiella pneumoniae has been used in cosmetics as deodorant (43) .
b. Cancer Therapy -Some siderophores, e.g, dexrazoxane, O-trensox, desferriexochelins, desferrithiocin, tachpyridine, have been found useful in cancer therapy (24) . bacteria, which produce and use siderophores to acquire iron (24-29).
Use of Gallium as Trojan Horse to Iron Seeking Bacteria
It is well known fact that iron is critical for the growth of bacteria and for their ability to form biofilms in slime encased bacteria that cause many chronic infections. In a study carried out at university of Washington, gallium, a metal very similar to iron (looks like iron) was used instead of iron. Because of structural similarity to iron, gallium is also chelated like iron by siderophores and siderophores are recognized by the cellular receptors on bacterial cells that allows the molecule (Siderophore-gallium complex) to enter inside the bacterial cells. Gallium was found to act Trojan horse to iron -seeking bacteria and killed them and inhibited biofilm formation. Gallium was also found effective against multiple antibiotic resistant strains of Pseudomonas aeruginosa. In mice, gallium treatment blocked both chronic and acute infections caused by Pseudomonas aeruginosa. This approach is under trial and results are promising (30).
Treatment of Iron Overload Diseases
Some siderophores are used in the treatment of acute iron intoxication and chronic iron overload diseases associated with excessive blood transfusions. In acute iron intoxication and chronic iron overload diseases, siderophores can be used as chelating agents, which are able to bind with iron to produce complexes that lead to formation of ferrioxamine. The ferrioxamine is soluble in water and readily excreted through the kidneys. It binds with iron in the blood and enhances its elimination via urine and faeces. Hence, it is of value in the treatment of acute iron intoxication and chronic iron overload diseases. Thus, it can be used to decrease the iron overload in the body.
These acute iron intoxication and chronic iron overload diseases include:
a. Haemochromatosis
Haemochromatosis is a disorder in which there is a prog ressive increase in the iron content of the body causing deposition of iron in the liver, heart or pancreas. It is the most common form of iron overload disease that occurs as a primary haemochromatosis (hereditary due to genetic abnormalities) or as a metabolic disorder. It causes body to absorb and store too much of iron from gastrointestinal tract. Haemosiderosis is a secondary haemochromatosis caused by excessive blood transfusions. Secondary haemochromatosis occurs as a result of severe chronic haemolysis, multiple frequent transfusions, excessive parenteral iron supplements and excess dietary iron intake. Clinically, haemochromatosis is manifested as joint pain -most common (Arthritis), fatigue, lack of energy, abdominal pain, loss of sex drive, heart problems, liver disease, such as cirrhosis, damage to pancreas, abnormal pigmentation of skin and damage to adrenal glands.
Treatment of haemochromatosis;
Desferal (Deferoxamine mesylate) is a chelating agent which binds with trivalent iron and form complexes that leads to formation of ferrioxamine. The complex ferrioxamine is soluble in water and readily excreted through the kidneys. It binds with iron in the blood and enhances its elimination via urine and faeces. Hence, it is of value in the treatment of haemochromatosis.
Doses and Administration; 6.0 gm in 24 hrs -not more than this is to be given intramuscularly or by slow subcutaneous injection or intravenous (IV) infusion. By intramuscularly or subcutaneous route it must be taken over 8-24 hrs due to its short duration of effect within body. Once its infusion stops, iron removal stops shortly thereafter, hence intermittent infusion has little effect on reducing iron overload. In chronic iron overload for infusion (21, 22) 
